The North American biotechnology and life sciences sector continues to play a significant role in advancing gene-editing technologies. Increasing investments in genomic research, precision medicine, and advanced therapeutic development are supporting the adoption of CRISPR and CRISPR-associated (Cas) gene technologies across the region. Research institutions, biotechnology companies, and...